Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 5INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Sarcoma 3Plasma cell 3Other hematologic neoplasm 3Breast 3Gastrointestinal 2Tumor-Agnostic 1Other solid neoplasm 1Lymphoid 1Genitourinary 1Dermatologic 1

Conditions

Solid Tumor 1

Interventions

Injections 98pembrolizumab 90Carboplatin 57Paclitaxel 54Cisplatin 52Nivolumab 44Docetaxel 43Pemetrexed 42Gemcitabine 37atezolizumab 32tislelizumab 29Bevacizumab 29toripalimab 23Fluorouracil 23Capecitabine 23Irinotecan 22Oxaliplatin 20durvalumab 19Ipilimumab 18Leucovorin 17Cetuximab 17Rifampin 14Itraconazole 14olaparib 13spartalizumab 12Midazolam 12Cyclophosphamide 12trifluridine tipiracil drug combination 11sintilimab 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × tanespimycin × Other solid neoplasm × Clear all
NCT00820768 2018-04-11

A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies

Celgene

Phase 1 Withdrawn
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡